Browsing Tag
Sangamo Therapeutics
4 posts
Sangamo Therapeutics wins FDA fast-track status for gene therapy ST-503 targeting small fiber neuropathy
Find out how Sangamo Therapeutics’ FDA fast-track win for ST-503 could reshape small fiber neuropathy treatment and shift biotech investor sentiment.
Will ST‑503 be the non‑opioid breakthrough in pain therapy? Sangamo gets Fast Track nod
Sangamo Therapeutics gains FDA Fast Track for ST-503, a gene therapy targeting chronic neuropathic pain. Find out what this means for non-opioid innovation.
FDA approval pathway propels Sangamo Therapeutics shares upward: what’s next?
Sangamo Therapeutics experienced a significant surge in its stock price, jumping by as much as 53%, after the…
Sangamo, Prevail Therapeutics ink deal for evaluating AAV capsids
Sangamo Therapeutics, a genomic medicine company, has entered an evaluation and option agreement with Prevail Therapeutics, an Eli…